Most Popular
-
1
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
2
Korea’s homegrown nanosatellite successfully launches into space
-
3
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
4
Nicaragua shuts down Seoul embassy
-
5
Medical reform committee kicks off despite boycott from doctors
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
Hybe's multilabel system tested amid conflict with Ador
-
7
SNU profs to suspend treatment for one day
-
8
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
-
9
Over-50s, men, single-person households take up majority of those filing for bankruptcy
-
10
SK hynix pledges W20tr to ramp up DRAM production at home
[DISCLOSURE] Korea United Pharm (033270) announced on Oct. 12 that its 38.4 billion won (US$34.18 million) contract with Jiangxi JiminKexin Group to supply its incrementally modified drug Cilostan Tabs has been canceled upon the Chinese company’s request. This amounts to 23.7 percent of the South Korean pharma company’s sales in 2015.
The contract to supply Clanza Tabs will remain in effect.
Cilostan reduces blood clots and Clanza relieves pain and inflammation.
(theinvestor@heraldcorp.com)
The contract to supply Clanza Tabs will remain in effect.
Cilostan reduces blood clots and Clanza relieves pain and inflammation.
(theinvestor@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/25/20240425050656_0.jpg&u=)
